Pressmeddelanden, rapporter och bolagsmeddelande för Dancann Pharma

An extraordinary general meeting of DanCann Pharma A/S was held on October 21, 2025, in Denmark. The main agenda was to approve a proposal by the board of directors to apply for a voluntary delisting of the company's shares from the Spotlight Stock Market and to amend the company's articles of association accordingly. Attorney-at-law Michael Kristensen chaired the meeting, confirming that it was properly convened with 75,000 votes represented. The proposal required a 2/3 majority vote, which was achieved as it was unanimously adopted. The board plans to apply for delisting on January 7, 2026, with the last expected trading day on January 22, 2026. After delisting, the company's shares will be traded over-the-counter. The meeting concluded with the proposal's adoption.

DanCann Pharma is undergoing significant organizational changes and strategic realignment. The founder and CEO, Jeppe Krog Rasmussen, has resigned to pursue new challenges. Peter Hauberg Søndergaard, previously the CFO, is set to become the new CEO, focusing on guiding the company through a delisting process, improving operational efficiency, and executing a long-term growth plan called Maturity2028. The company plans to voluntarily delist from the Spotlight Stock Market due to high costs, administrative burdens, strategic realignment, reduced capital needs, and limited investor interest and liquidity. The delisting aims to allow DanCann Pharma to allocate resources more efficiently and secure capital through private channels. The Board believes these changes, including the leadership transition and delisting, are in the company's and shareholders' best interest, aiming for future profitability and sustainable growth.

DanCann Pharma A/S has scheduled an extraordinary general meeting for 21 October 2025 to discuss a proposal for voluntarily delisting the company's shares from the Spotlight Stock Market. The board of directors recommends this action due to high costs, administrative burdens, strategic realignment, and limited investor interest. Approval requires a two-thirds majority vote. If approved, the delisting application will be submitted on 7 January 2026, with the last trading day expected on 22 January 2026. Shareholders can attend the meeting in person, by proxy, or vote by post. The meeting will be conducted in English, and relevant documents are available on the company’s website.

DanCann Pharma A/S, a Danish biopharmaceutical company founded in 2018, plans to delist its shares from the Spotlight Stock Market. The decision follows a strategic shift since 2023, focusing on sourcing, import, and distribution, with reduced capital needs and a leaner organization. The board cites high costs and administrative burdens of remaining listed, limited investor interest, and better alignment with private equity markets as reasons for delisting. The proposal requires approval at an extraordinary general meeting and, if accepted, the application for delisting will be submitted on January 7, 2026, with the last trading day expected on January 22, 2026. Post-delisting, shares will trade over-the-counter, and the company will no longer adhere to certain public disclosure obligations but will continue operations and pursue strategic partnerships through private equity.

The financial summary for DanCann Pharma A/S for Q2-2025 shows a decrease in net sales and an increase in losses compared to the same period in 2024. The company experienced continued competitive pressure on its products Bedrocan® and Bediol®. Two new products, Bedrolite® and Bedrobinol®, were added to the portfolio, with their first contributions expected in Q3. The divestment of the production facility Biotech Pharm1 (BP1) is in its final stage. The Chairman of the Board, Carsten Trads, noted ongoing challenges but expressed optimism about future growth, particularly with the new product launches and strategic initiatives. The company's equity ratio remained stable at 0.66 compared to 0.32 in the previous year. DanCann Pharma A/S is a Danish biopharmaceutical company focused on cannabinoids, listed on the Spotlight Stock Market. The report includes forward-looking statements subject to risks and uncertainties.

DanCann Pharma A/S has entered into a DKK 2 million bridge loan agreement with a group of ten investors, including its largest shareholder, JEQ Capital AB. The loan is unsecured and does not involve related parties. It includes a 15% upfront fee and a 2% monthly fee. Lenders can convert their loan and fees into company shares at a price based on the recent average trading price of DKK 1.13 per share. The company can repay the loan at any time with a ten-day notice. If a capital raise occurs before repayment, lenders can convert their loan into underwriting commitments. DanCann Pharma A/S was founded in 2018, is focused on cannabinoids, and is listed on the Spotlight Stock Market. The company warns that forward-looking statements in the release are subject to risks and uncertainties that may affect actual results.

DanCann Pharma is in advanced negotiations to sell its production facility, BP1, to a European investment group focused on the energy sector. The group plans to use the facility for producing pharmaceutical-grade cannabis, targeting export markets like Germany. The conditional sales agreement is valued at EUR 1.25 million, with DanCann Pharma expected to net approximately EUR 0.75 million after excluding real estate, which is owned by a third party. The sale includes a bonus clause contingent on successful facility reapproval. DanCann Pharma has secured a bridge loan of DKK 2 million to maintain liquidity until the sale's initial payments are received. The company is also launching a new strategic plan, Maturity2028, focusing on positive cash flow, product expansion, potential mergers and acquisitions, and improved investor relations. The sales agreement remains non-binding, pending due diligence and alignment with the buyer's requirements, with exclusivity granted to the buyer for 60 days.

DanCann Pharma A/S rapporterar sina finansiella resultat för första kvartalet 2025. Brutto- och nettoomsättningen minskade jämfört med samma period föregående år. EBITDA och driftsresultatet (EBIT) visade negativa siffror, men förbättrades något jämfört med första kvartalet 2024. Soliditetsgraden ökade till 0,84 från 0,40. CEO Jeppe Krog Rasmussen kommenterar att första kvartalet traditionellt är dämpat och att företaget möter ökad konkurrens och produktreturer, vilket har lett till justeringar i inköpsstrategin och interna initiativ för att skydda marginalerna och förbättra effektiviteten. Företaget har gjort framsteg inom sin receptbaserade pipeline och erhållit regulatoriska godkännanden för flera produkter. En exklusiv distributionsavtal har ingåtts med Tetra Pharm Technologies ApS för det danska marknaden, vilket inkluderar deras patenterade leveranssystem ZYNDIKATE®. DanCann förbereder också lanseringen av nya OTC-produkter som en del av sin tillväxtstrategi. DanCann Pharma A/S är ett danskt biofarmaceutiskt företag fokuserat på cannabinoider och är noterat på Spotlight Stock Market. Företaget publicerar också ett förbehåll om framåtblickande uttalanden, där de varnar för riskerna och osäkerheterna som kan påverka framtida resultat.

Summary: DanCann Pharma A/S reported financial results for Q1 2025, showing gross revenue of DKK 558,000, a decline from DKK 702,000 in Q1 2024. The company faced a net sales drop to DKK 298,000 and a negative EBITDA of DKK -2,275,000. Operating loss (EBIT) was DKK -2,774,000, and the result per share was DKK -0.5937. The equity ratio improved to 0.84. CEO Jeppe Krog Rasmussen noted challenges due to market competition and regulatory changes, prompting adjustments in procurement and internal strategies. The company advanced its prescription pipeline with approvals for several products and signed a distribution agreement with Tetra Pharm Technologies. DanCann is also preparing to launch OTC/DTC products to diversify revenue. The company remains focused on disciplined growth and delivering shareholder value. Forward-looking statements highlight potential risks and uncertainties.

DanCann Pharma har fått godkännande från den danska läkemedelsmyndigheten för distribution av två nya produkter, Bedrolite® och Bedrobinol®, inom den danska marknaden för medicinsk cannabis. Detta stärker företagets position i Danmark och visar deras engagemang för att öka patienternas tillgång till standardiserade cannabinoidbaserade behandlingar. Bedrolite® är en CBD-dominerande produkt, medan Bedrobinol® är THC-dominerad. Båda produkterna är avsedda för inhalation och ingår i det danska pilotprogrammet för medicinsk cannabis, vilket innebär att de kan förskrivas av läkare och är berättigade till statlig ersättning. Förväntad lansering är juni/juli 2025. Produkterna är en del av DanCann Pharmas strategi att erbjuda ett brett spektrum av terapeutiska alternativ och förväntas bidra positivt till företagets försäljning och konkurrenskraft. CEO Jeppe Krog Rasmussen uttrycker att detta är ett viktigt steg för att förbättra tillgången till högkvalitativa cannabinoidbaserade läkemedel.